Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain scans reveal why some dementia patients lack Self-Awareness

NCT ID NCT06794580

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 77 people with Alzheimer's or frontotemporal dementia to understand why some lose awareness of their condition (anosognosia). Researchers used EEG and brain scans to measure how the brain responds to mistakes and emotional signals. The goal is to find brain markers that could one day help develop tools to improve self-awareness in early dementia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could point toward new ways to detect and improve self-awareness in early dementia, possibly leading to brain-training tools.
What could go wrong
This is a small, completed observational study, not a treatment trial. The findings may not lead to practical therapies, and any future applications are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

77 people

The number who actually took part.

Started

Jan 2019

Finished

Nov 2021

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

We plan to recruit a total of 100 subjects, including 30 patients with bvFTD, 30 patients with AD, and 40 healthy, age-, gender-, and education level-matched controls. Since the project aims at investigating the mechanistic cascade that makes bvFTD and AD patients to become unaware of their deficits, the testing of such patients and healthy controls is necessary.

Ages

50 to 85 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: PATIENTS and HEALTHY CONTROLS : * French speakers\*, age ≥ 50 ≤ 85 years of age, with normal color vision or corrected-tonormal visual acuity, * Capacity to consent, * Covered by social security, * Ability to undergo MRI scanning, * The spouse / caregiver is able to accompany the subject to both visits and ready to complete questionnaires. * Already in menopause (for women) PATIENTS : 30 patients fulfilling the core diagnostic features of bvFTD; 30 patients fulfilling the core diagnostic features of AD; both in a mild to moderate cognitive and functional severity stage, as determined by: MMSE score greater than or equal to 18, and CDR global score less than or equal to 2, Grober et Buschke: TRGB \< 42 as well as clinical signs (subjective impression) of anosognosia. HEALTHY SUBJECTS (n=40) : MMSE score ≥ 27;TRGB\> 42 Education, gender-, and aged-matched controls. \* Subjects will be administered neuropsychological tests that have been validated for French speakers. Exclusion Criteria: * Illiteracy /unable to count or to read; * Having a neurological disorder, such as: epilepsy, extrapyramidal signs, brain tumour, subdural haematoma, history of head trauma followed by persistent neurological deficits (motor, sensory or cognitive); stroke that has occurred in the last three months; * Report of a present or prior major psychiatric disorder; * Potentially confounding medications, particularly beta-blockers that may have effects on the peripheral nervous system; typically, beta-blockers are used to control heart rhythm, treat angina, and reduce high blood pressure. * Person deprived of their liberty by judicial or administrative decision * Participation in a drug trial or exclusion period of another study * Inability to understand information about the protocol * Meeting brain MRI exclusion criteria (pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin, or body, claustrophobia) or refusing MRI. \* Contra-indication questionnaire to be filled in beforehand.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A)

    Paris, Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.